Harbin Gloria Pharma pay $380 million to acquire an 85% stake in Shanxi Powerdone, which makes chemical drugs and compound preparations.
To pay for the transaction, Gloria will raise $960 million in a private placement.
In addition, Gloria will allocate another $183 million in capex to several company infrastructure improvements.
And, two months ago, Gloria spent $24 million to acquire the remaining 30% stake in Guangzhou Xinhuacheng Biotech, gaining a production base for ginkgolide B injections.
For further deal information visit Current Agreements (subscription required)
Scorecard: Top partnering deals by value in 2014
View: Top biotech companies